Drug development for ulcerative proctitis: current concepts

Gut. 2021 Jul;70(7):1203-1209. doi: 10.1136/gutjnl-2021-324108. Epub 2021 Mar 31.

Authors

Bénédicte Caron¹, William J Sandborn², Stefan Schreiber³, Remo Panaccione⁴, Silvio Danese⁵, Laurent Peyrin-Biroulet⁶

Affiliations

¹ Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France.
² Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
³ Department of Internal Medicine, University Hospital Schleswig-Holstein, Kiel, Germany.
⁴ Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
⁵ Department of Biomedical Sciences, Humanitas Clinical Research Center-IRCCS and Humanitas University, Milan, Italy.
⁶ Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France peyrinbiroulet@gmail.com.

PMID: 33789968
DOI: 10.1136/gutjnl-2021-324108

No abstract available

Keywords: clinical trials; ulcerative colitis.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Administration, Oral
Administration, Rectal
Adrenal Cortex Hormones / therapeutic use
Anti-Inflammatory Agents / therapeutic use
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Colitis, Ulcerative / drug therapy*
Drug Development
Endpoint Determination
Gastrointestinal Agents / administration & dosage
Gastrointestinal Agents / therapeutic use*
Humans
Immunosuppressive Agents / therapeutic use*
Mesalamine / therapeutic use
Proctitis / diagnosis*
Proctitis / drug therapy*
Randomized Controlled Trials as Topic
Sigmoidoscopy
Tacrolimus / therapeutic use
Treatment Outcome

Substances

Adrenal Cortex Hormones
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Gastrointestinal Agents
Immunosuppressive Agents
Mesalamine
Tacrolimus

Grants and funding

P30 DK120515/DK/NIDDK NIH HHS/United States